Key result
A novel three-CpG methylation risk score is linked to ~175% higher odds of elevated cIMT.
Why the study?
Cardiovascular disease research remains Eurocentric despite etiological differences across ancestries, and incorporating Asian populations can enhance understanding of cIMT biology and subclinical CVD processes.
Meta-Analysis (n=2,765)
Yes
Odds Ratio: 2.75 (95% CI 1.47–5.13)
An epigenome-wide association study in an Asian cohort identified three novel DNA methylation markers for carotid intima-media thickness, suggesting a methylation-mediated mechanism for coronary artery disease risk via NBEAL2 regulation.
Methylation scores should not yet inform practice; hypothesis-generating for epigenetic atherosclerosis risk and requires prospective validation.
ABSTRACT Background Carotid-intima media-thickness predicts cardiovascular events and informs mechanistic research on cardiovascular diseases (CVD). However, CVD research remains Eurocentric despite etiological differences across ancestries. Incorporating Asian populations— who face substantial CVD burden with distinct etiological landscape— can enhance our understanding of cIMT biology and subclinical processes linked to CVD. This study aimed to elucidate methylation-based mechanisms of cIMT through DNA methylation profiling integrated with multi-omics data and clinically informative cIMT thresholds, leveraging an Asian cohort to enhance discovery. Methods We conducted an epigenome-wide association study (EWAS) of cIMT using peripheral blood DNA methylation at ∼850,000 CpG sites in the Asian Health for Life in Singapore (HELIOS) cohort (n=1,357), followed by targeted trans-ancestry meta-analysis with European cohorts (overall n=2,765). Causal inference analyses (summary data-based Mendelian Randomisation [SMR] and colocalisation) evaluated methylation-mediated effects on cIMT, CVD and proximal gene expression. We derived a methylation risk score (MRS) and tested its association with cIMT thresholds indicative of elevated cardiovascular risk (≥75 th percentile for age, sex and ethnicity). Results Three novel CpG-cIMT associations were identified (P<9.35E-07). Causal analyses supported cg08227773 methylation-mediated effects on both coronary artery disease risk (P SMR =2.91E-05, coloc PP.H4 =0.91) and NBEAL2 (Neurobeachin-like 2) expression (P SMR =9.13E-08, coloc PP.H4=0.69), a gene implicated in immune dysregulation. MRS of cIMT aggregating the three sentinel CpGs was associated with clinically-informative cIMT elevation (Odds Ratio=2.75 for Q4 vs Q1, 95% CI: 1.47-5.13). Conclusions Through Asian-led discovery, this study identifies three novel DNA methylation markers for cIMT that are linked to cIMT elevation above clinically meaningful risk thresholds. Causal inference analyses suggest methylation-mediated CAD risk via NBEAL2 regulation, nominating biologically relevant targets while underscoring the need for larger multi-omics resources to refine mechanisms.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2025) conducted a meta-analysis in Carotid Intima-Media Thickness (n=2,765). Methylation risk score (MRS) for cIMT (Quartile 4) vs. Methylation risk score (MRS) for cIMT (Quartile 1) was evaluated on Clinically-informative cIMT elevation (≥75th percentile for age, sex and ethnicity) (OR 2.75, 95% CI 1.47-5.13). A methylation risk score aggregating three novel CpG markers was associated with clinically meaningful elevation in carotid intima-media thickness (OR 2.75 for highest vs lowest quartile).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: